Targeting CD30 in patients with Hodgkin lymphoma Book Section
| Authors: | Kumar, A.; Pileri, S.; Younes, A.; Engert, A. |
| Editors: | Andreas, E.; Younes, A. |
| Article/Chapter Title: | Targeting CD30 in patients with Hodgkin lymphoma |
| Abstract: | The introduction of multi-agent chemotherapy for the treatment of Hodgkin lymphoma is one of the major breakthroughs in clinical oncology. Treatment with multi-agent chemotherapy and improved radiation methods has significantly improved the chance of curing these patients from less than 5 % in 1963 to about 80 % at present. However, there is still a substantial need to improve current treatment approaches particularly for elderly patients or those with relapsed and refractory disease. Cured patients unfortunately are at high risk for late side effects including second malignancies, cardiac toxicity, infertility, and fatigue. Thus, there is a clear need for new and safer drugs that are more selective in targeting the malignant Hodgkin and Reed-Sternberg (HRS) cells in this disease while sparing normal tissues. © Springer International Publishing Switzerland 2015. |
| Book Title: | Hodgkin Lymphoma: A Comprehensive Overview. 2nd ed |
| ISBN: | 978-3-319-12504-6 |
| Publisher: | Springer |
| Publication Place: | Cham, Switzerland |
| Date Published: | 2015-01-01 |
| Start Page: | 343 |
| End Page: | 354 |
| Language: | English |
| DOI: | 10.1007/978-3-319-12505-3_21 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Book Chapter: 21 -- Export Date: 3 March 2016 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work